Article info
PDFResearch ethics
Paper
Two concepts of therapeutic optimism
- Correspondence to Lynn A Jansen, Associate Research Professor (Prov), Madeline Brill Nelson Chair in Ethics Education and Associate Director, Center for Ethics in Health Care, Oregon Health and Science University, 3181 SW, Sam Jackson Park, RD (UHN-86) Portland, OR 97239, USA; ljhomes{at}aol.com
Citation
Two concepts of therapeutic optimism
Publication history
- Received September 27, 2010
- Revised February 28, 2011
- Accepted March 2, 2011
- First published May 7, 2011.
Online issue publication
August 19, 2011
Article Versions
- Previous version (7 May 2011).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Other content recommended for you
- Unrealistic optimism and the ethics of phase I cancer research
- Understanding people’s ‘unrealistic optimism’ about clinical research participation
- Phase 1 oncology trials and informed consent
- Perceptions of control and unrealistic optimism in early-phase cancer trials
- Informed consent for early-phase clinical trials: therapeutic misestimation, unrealistic optimism and appreciation
- Therapeutic appropriation: a new concept in the ethics of clinical research
- Phase I oncology trials: why the therapeutic misconception will not go away
- Navigating choice in the face of uncertainty: using a theory informed qualitative approach to identifying potential patient barriers and enablers to participating in an early phase chimeric antigen receptor T (CAR-T) cell therapy trial
- Faith, Hope And (No) Clarity
- Therapeutic optimism in the consent forms of phase 1 gene transfer trials: an empirical analysis